NuRenal Intro - INVESTORS 2024

Shaping the Future of Dialysis Care

START

INDEX

nurenal software

01 · Market Analysis

02 · Dialysis Industry

03 · Intro

04 · Business Model & Stategy

05 · Customers & Case Studies

06 · Market Insights

07 · Metrics

NuRenal is designed to streamline and optimize the operations of dialysis organizations, with user-friendly and powerful tools.

MARKET ANALYSIS

GLOBAL Market Breakdown​

Market analysis

3 MILLION

GLOBAL DIALYSIS PATIENTS

15%

800k

4%

North America

40%

450k

3.5%

Europe

26.7%

6.7%

1.2M

7%

Asia-Pacific

11.7%

Market growth

350K

4.5%

Latin America

200K

5%

Middle East & Africa

u.s. dialysis patients

BROKEN BY PROVIDER TYPE

LARGE

NUMBER OF patients:

208,007

Fresenius

Dialysis Clinic Inc.

519,242

14,969

total u.S. patients

204,000

MEDIUM

DaVita

8,209

MEDIUM

Satellite

U.S. Renal Care

25,327

LARGE

41,712

LARGE

Independent

Innovative Renal Care

17,018

MEDIUM

source: STATISTICS.COM

MARKET PROJECTION & OPPORTUNITY

2025

20K

Annually

3 Millionpatients

us PATIENT Growth

SCALABLE BUSINESS MODEL

Unmet Needs in Dialysis Care

Shift Toward Home Dialysis

Payment adjustment

THE FUTUREOF DIALYSIS

ai powered analytics & monitoring

PORTABLE & WEARABLE DIALYSIS DEVICES

HOME DIALYSIS INNOVATIONS &TELEHEALTH

VALUE BASED CARE & TECHNOLOGICAL ADVANCEMENTS

PERSONALIZED CARE

early intervation& preventive care

PAYMENT MODELS

conclusion & key takeaways

market analysis

The U.S. dialysis market will continue to grow, driven by rising patient numbers and innovative technologies.​

Providers that embrace personalized care and value-based models will thrive in the evolving landscape.​

Home dialysis will play a pivotal role, with wearable technologies and AI transforming patient care.​

SLIDE PREVIOUSLY HIDDEN*

BUSINESS MODEL & STRATEGY

BUSINESS MODEL

Based on monthly subscription plans with 3 years contracts

BILLING

CKD

EMR

ERP

$20moPER PATIENT

$20moPER PATIENT

(ALL INCLUSIVE)

(ALL INCLUSIVE)

$26MOPER PATIENT

2.5 % of total clinic revenue

(ALL INCLUSIVE)

(ALL INCLUSIVE)

$15moper user

2.5 % of total clinic revenue

(ALL INCLUSIVE)

(PER MODULE)

CUSTOMERS

CURRENT & UPCOMING REACH

BETA PROGRAM

400

417

KidneySpa

RENVIVA

572

200

American Kidney Center

Central Florida Kidney Centers

305

1.9K

Physicians Choice

Atlantis Health Care Group

PATIENT REACH

271

PhysiciansDialysis

45

Kidney Kare

Total Centers & Patients:65 CENTERS & 1,400 PATIENTS

190

Lakes Dialysis

CASE STUDIES

Streamlining Operations with

CASE STUDIES

BETA PROGRAMS

Compliance Monitoring

Patient Schedule

Employee Engagement

Physicians dialysis

KIDNEYspa

KIDNEY kare

Replaced paper-based logs resulted in timely and accurate patient care while simplifying audit procedures.

Replaced complex manual scheduling with an automated, real-time system. Front desk saves 236 hours yearly Managers save 65 hours yearly

Tranforming their employee documentation and compliance management processes resulted in a Zero Deficiencies ACHA inspection.

COMPETITOR ANALYSIS

COMPETITOR ANALYSIS

Advanced Analytics

Intake &Registration

PatientEngagement

Coordinationof Benefits

Verification &Authorization

ProtocolManagement

Employee Engagement& Training

PayorManagement

Physician Rounding

SOP / Policies & Procedures

Document& Contracts

Procurement& Inventory

Compliance& Regulatory

Clinical Management

Cost Reports

ERP

EMR

RCM

METRICS

10 YEARS GROWTH

SKYROCKETING GROWTH ESTIMATE

NuRenal erp

NuRenal RCM

NuRenal EMR

EXPENSE

REVENUE

EBITDA

EXPECTED PATIENT GROWTH

10 YEAR GROwth

SLIDE PREVIOUSLY HIDDEN*

THE ASK

By 2026, NuRenal could reach a valuation of $38.23 million with 6,000 U.S. patients and up to $382.32 million once we scale to 50,000 global patients, assuming less than 2% of market penetration.

We are looking for $2 Millions in funds for a 10% equity stake in our company in order to accelerate the roll out of NuRenal ERP and hire key staff to finish development of our NuRenal EMR and RCM products

SOFTWAREDEVELOPMENT

EMR & RCM

ERP PHASE 2

Expand sales and increase NuRenal ERP implantation

HIRE KEY STAFF

Leadershop, Sales and Data Analytics

The investment gain

Your estimated Annual Return of Investment is 57.15%!

INVESTMENTGAIN

$8,584,643

ROI

858.46%

ANNUALIZED ROI

57.15%

INVESTMENTLENGHT

5 YEARS

CONCLUSION

NuRenal has the potential to significantly increase its valuation by focusing on key growth drivers such as accelerating patient base growth, launching high-value products (EMR and RCM), expanding internationally, and investing in AI capabilities.

If you have questions or would like to invest in NuRenal, please don't hesitate to reach out to us.

hello@nurenal.com